Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Maria Gomez

Maria Gomez

Professor

Maria Gomez

Attenuation of Experimental Atherosclerosis by Interleukin-19.

Author

  • Stephen Ellison
  • Khatuna Gabunia
  • Sheri E Kelemen
  • Ross N England
  • Rosario Scalia
  • James M Richards
  • Wayne Orr
  • James G Traylor
  • Thomas Rogers
  • William Cornwell
  • Lisa Berglund
  • Isabel Goncalves
  • Maria Gomez
  • Michael V Autieri

Summary, in English

Interleukin-19 (IL-19) is a putative Th2, anti-inflammatory interleukin. Its expression and potential role in atherogenesis are unknown. IL-19 is not detected in normal artery and is expressed to a greater degree in plaque from symptomatic versus asymptomatic patients, suggesting a compensatory counter-regulatory function. We tested whether IL-19 could reduce atherosclerosis in susceptible mice and identified plausible mechanisms.

Department/s

  • Cardiovascular Research - Immunity and Atherosclerosis
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2013

Language

English

Pages

2316-2324

Publication/Series

Arteriosclerosis, Thrombosis and Vascular Biology

Volume

33

Issue

10

Document type

Journal article

Publisher

Lippincott Williams & Wilkins

Topic

  • Cardiac and Cardiovascular Systems

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis

ISBN/ISSN/Other

  • ISSN: 1524-4636